IDO1 is an enzyme tumours use to burn up tryptophan, starving T cells and producing by-products that switch them off. Epacadostat blocked it but its programme ended in failure; the IO102-IO103 vaccine instead teaches T cells to attack the IDO1-expressing cells themselves. This dossier gathers the 2 products (0 approved), 2 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
The two corpus approaches differ in kind: epacadostat blocked the enzyme's chemistry, while IO102-IO103 raises T cells against cells that express IDO1 or PD-L1 in the tumour microenvironment, turning the suppressive cells themselves into targets.
- Tumour cells and myeloid cells of the tumour microenvironment
- Melanoma and head and neck cancer (IO102-IO103); melanoma (epacadostat)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →| Modality | Phase 3 | Withdrawn or failed |
|---|---|---|
| Small molecule 1 | - | |
| Vaccine or virus 1 | - |
Trials
Evidence ranking →| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Active | An Open-label, Randomized, Phase 3 Clinical Trial of IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Patients With Previously Untreated, Unresectable, or Metastatic (Advanced) Melanoma (IO102-IO103-013 / MK3475-D18) | - | ||
| 2 | Recruiting | Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors | - |
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Literature
Preprints →Query for this target: (TITLE:"IDO1" OR ABSTRACT:"IDO1" OR TITLE:"IDO" OR ABSTRACT:"IDO" OR TITLE:"INDO" OR ABSTRACT:"INDO" OR TITLE:"indoleamine 2,3-dioxygenase 1" OR ABSTRACT:"indoleamine 2,3-dioxygenase 1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IDO1, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ido1.json. Licence CC BY-NC 4.0.